Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line

Hogendoorn, 2013, Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma, 264 Inwards, 2013, Dedifferentiated chondrosarcoma, 269 Nakashima, 2013, Mesenchymal chondrosarcoma, 271 McCarthy, 2013, Clear cell chondrosarcoma, 273 Gelderblom, 2008, The clinical approach towards chondrosarcoma, Oncologist, 13, 320, 10.1634/theoncologist.2007-0237 Dantonello, 2008, Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups, Cancer, 112, 2424, 10.1002/cncr.23457 Frezza, 2015, Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study, Eur J Cancer, 51, 374, 10.1016/j.ejca.2014.11.007 Huvos, 1983, Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment, Cancer, 51, 1230, 10.1002/1097-0142(19830401)51:7<1230::AID-CNCR2820510710>3.0.CO;2-Q Schneiderman, 2016, Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database, Clinical Orthopaedics and Related Research®, 475, 799, 10.1007/s11999-016-4779-2 Wang, 2012, Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data, Genes Chromosomes Cancer, 51, 127, 10.1002/gcc.20937 Mosquera, 2013, Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma, Genes Chromosomes Cancer, 52, 538, 10.1002/gcc.22050 Jin, 2012, Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes, Genes Chromosomes Cancer, 51, 510, 10.1002/gcc.21939 Strehl, 2008, ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations, Clin Cancer Res, 14, 977, 10.1158/1078-0432.CCR-07-4022 Carapeti, 1998, A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia, Blood, 91, 3127, 10.1182/blood.V91.9.3127 Bishop, 2015, Mesenchymal chondrosarcoma in children and young adults: a single institution retrospective review, Sarcoma, 2015, 608279, 10.1155/2015/608279 Cesari, 2007, Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution, Tumori, 93, 423, 10.1177/030089160709300503 Harwood, 1981, Mesenchymal chondrosarcoma: a report of 17 cases, Clin Orthop Relat Res, 158, 144, 10.1097/00003086-198107000-00023 Shakked, 2012, Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases, Arch Pathol Lab Med, 136, 61, 10.5858/arpa.2010-0362-OA Xu, 2015, Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years, PLoS One, 10, e0122216, 10.1371/journal.pone.0122216 Terek, 1998, Chemotherapy and P-glycoprotein expression in chondrosarcoma, J Orthop Res, 16, 585, 10.1002/jor.1100160510 van Oosterwijk, 2012, Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance, Ann Oncol, 23, 1617, 10.1093/annonc/mdr512 Wyman, 1999, Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance, J Orthop Res, 17, 935, 10.1002/jor.1100170619 van Oosterwijk, 2013, Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets, Am J Pathol, 182, 1347, 10.1016/j.ajpath.2012.12.036 Hata, 2015, The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics, Cancer Discov, 5, 475, 10.1158/2159-8290.CD-15-0011 Pajor, 1998, Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukemia, Cytometry, 34, 87, 10.1002/(SICI)1097-0320(19980415)34:2<87::AID-CYTO5>3.0.CO;2-9 Baranski, 2015, Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma, J Pathol, 236, 348, 10.1002/path.4528 Greco, 1995, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, 47, 331 Borisy, 2003, Systematic discovery of multicomponent therapeutics, Proc Natl Acad Sci USA, 100, 7977, 10.1073/pnas.1337088100 Brown, 2003, Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications, Ann Clin Lab Sci, 33, 131 Brown, 2004, Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma, Ann Clin Lab Sci, 34, 397 Park, 2000, Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma, Oncol Rep, 7, 1041 Cragg, 2009, Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics, Nat Rev Cancer, 9, 321, 10.1038/nrc2615 Vela, 2015, Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside, Curr Opin Pharmacol, 23, 74, 10.1016/j.coph.2015.05.014